Ibalizumab
This article was based on formal and / or substantive defects on the quality assurance side of the editorial Medicine entered. Please help fix the shortcomings in this article and join the discussion there . The minimum requirements for medical articles are to be met, thereby avoiding a possible deletion of the article or article passages within four weeks. |
Ibalizumab | ||
---|---|---|
other names |
|
|
Identifier | ||
External IDs |
|
|
Drug information | ||
DrugBank | DB12698 | |
Drug class | Monoclonal antibody |
Ibalizumab is the first humanized monoclonal antibody for the treatment of HIV infection . Ibalizumab was approved by the FDA in 2018 .
Working principle
Ibalizumab blocks the CD4 receptor .
Indications
Treatment of multidrug-resistant HIV-1 infection in combination with other antiretroviral drugs.
Contraindications
Individual evidence
- ^ Novel Drug Approvals for 2018 . FDA .
- ↑ Anthony Markham: Ibalizumab: First Global Approval . In: Drugs . tape 78 , no. 7 , May 2018, p. 781 , doi : 10.1007 / s40265-018-0907-5 , PMID 29675744 .
- ↑ TROGARZO- Ibalizumab injection, solution . DailyMed .